Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 4/20 | 0.68 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.68 |
| ▸ | MAOA | P21397 | 1/20 | 0.68 |
| ▸ | DRD2 | P14416 | 3/20 | 0.57 |
| ▸ | DRD4 | P21917 | 3/20 | 0.57 |
| ▸ | DRD3 | P35462 | 3/20 | 0.57 |
| ▸ | NPC1 | O15118 | 2/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.54 |
| ▸ | CD74 | P04233 | 1/20 | 0.53 |
| ▸ | MIF | P14174 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | KDM1A | O60341 | 1/20 | 0.50 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17502323 | 0.85 | KDM4E (0.74) | NOTUML3MBTL1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL3614213 | 0.81 | NOTUM (0.68) | NOTUML3MBTL1MAOADRD2DRD4 | |
| SCHEMBL3777938 | 0.81 | NOTUM (0.68) | NOTUML3MBTL1MAOADRD2DRD4 | |
| SCHEMBL2821461 | 0.81 | NOTUM (1.00) | NOTUML3MBTL1MAOAKDM4EMAPT | |
| SCHEMBL16401577 | 0.81 | NOTUM (1.00) | NOTUML3MBTL1MAOADRD2DRD4 | |
| SCHEMBL28064712 | 0.81 | NOTUM (0.68) | NOTUML3MBTL1MAOADRD2DRD4 | |
| Bromide SCHEMBL1882333 | 0.79 | NOTUM (0.66) | NOTUML3MBTL1MAOADRD2DRD4 | |
| SCHEMBL12601113 | 0.78 | NOTUM (0.64) | NOTUML3MBTL1MAOADRD2DRD4 | |
| SCHEMBL16271168 | 0.78 | NOTUM (0.64) | NOTUML3MBTL1MAOADRD2DRD4 | |
| SCHEMBL27711741 | 0.78 | NOTUM (0.64) | NOTUML3MBTL1MAOADRD2DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025085347-A1 | IL4I1 INHIBITORS AND USES THEREOF | MERCK SHARP & DOHME LLC (US) | 2025-04-24 | — | — | WO | disclosed |
| US-11885818-B2 | Reagent for mass spectrometry | ROCHE DIAGNOSTICS OPERATIONS, INC. (US) | 2024-01-30 | — | — | US | disclosed |
| US-20210140983-A1 | REAGENT FOR MASS SPECTROMETRY | ROCHE DIAGNOSTICS OPERATIONS, INC. | 2021-05-13 | — | — | US | disclosed |
| US-20210140983-A1 | REAGENT FOR MASS SPECTROMETRY | ROCHE DIAGNOSTICS OPERATIONS, INC. | 2021-05-13 | — | — | US | disclosed |
| CN-112492881-A | Reagent for mass spectrometry | 豪夫迈·罗氏有限公司 | 2021-03-12 | — | — | CN | disclosed |
| WO-2009153536-A1 | 1-AZA-BICYCLO [2.2.2] OCTANE DERIVATIVES USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | ARGENTA DISCOVERY LIMITED (GB) | 2009-12-23 | — | — | WO | disclosed |
| WO-2009153536-A1 | 1-AZA-BICYCLO [2.2.2] OCTANE DERIVATIVES USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | ARGENTA DISCOVERY LIMITED (GB) | 2009-12-23 | — | — | WO | disclosed |
| WO-2009139709-A1 | QUINUCLIDINE DERIVATIVES AND THEIR USE AS MUSCARINIC RECEPTOR ANTAGONISTS FOR THE TREATMENT OF ASTHMA AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) | ASTRAZENECA AB (SE) | 2009-11-19 | — | — | WO | disclosed |
| WO-2009139709-A1 | QUINUCLIDINE DERIVATIVES AND THEIR USE AS MUSCARINIC RECEPTOR ANTAGONISTS FOR THE TREATMENT OF ASTHMA AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) | ASTRAZENECA AB (SE) | 2009-11-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210140983-A1 | REAGENT FOR MASS SPECTROMETRY | SRMS, PTMS, MMAB | NOTUM 212/4885L3MBTL1 2526/4885MAOA 854/4885 |
| US-11885818-B2 | Reagent for mass spectrometry | SRMS, PTMS, MMAB | NOTUM 212/4885L3MBTL1 2526/4885MAOA 854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.